GlassScriptPhysician profile
Keith Arnold Wied
NPI 1497712350
$5,430.41
in general payments reported to CMS, 2019-2025
30 companies · $1,096 in 2025
The $1,096 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.36 · 2020: $684 · 2021: $874 · 2022: $723 · 2023: $1,213 · 2024: $778 · 2025: $1,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,087.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,485.33 | 2021-2025 | Skyrizi, Rinvoq, Creon |
| Boston Scientific Corporation | $990.20 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $369.74 | 2021-2025 | Entyvio, Gattex |
| Celgene Corporation | $344.00 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $284.08 | 2020-2025 | Tremfya, Stelara |
| Ferring Pharmaceuticals INC. | $190.88 | 2023-2025 | Rebyota, Clenpiq |
| Phathom Pharmaceuticals, INC. | $175.25 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $161.47 | 2024-2025 | Vowst |
| Madrigal Pharmaceuticals | $151.90 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $140.87 | 2023-2025 | Dupixent |
| Genzyme Corporation | $137.95 | 2023-2025 | |
| Pfizer INC. | $136.68 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $124.28 | 2022-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $116.56 | 2021-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $91.96 | 2019-2023 | Ocaliva |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $74.12 | 2022-2024 | Ibsrela |
| Celltrion USA INC. | $64.14 | 2024-2025 | Vegzelma |
| Gilead Sciences, INC. | $46.08 | 2021-2025 | |
| Braintree Laboratories, INC. | $45.20 | 2022-2025 | Sutab, Suflave |
| Biocon Biologics INC | $41.20 | 2025 | Yesintek |
| Lilly USA, LLC | $40.06 | 2024-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $37.34 | 2021-2023 | |
| Redhill Biopharma INC. | $36.14 | 2021 | |
| Conmed Corporation | $33.34 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.55 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $30.78 | 2021 | |
| Apollo Endosurgery US INC | $28.18 | 2022 | |
| Erbe USA INC | $15.13 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $5.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$31,967.77 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Wied listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.